Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
David M Hyams, Arlene Chan, Celia de Oliveira, Raymond Snyder, Jeferson Vinholes, M William Audeh, Victor M Alencar, Janine Lombard, Bijoyesh Mookerjee, John Xu, Kathryn Brown, Paula Klein
INVESTIGATIONAL NEW DRUGS | SPRINGER | Published : 2013
Hormone receptor-positive breast cancer is treated with estrogen inhibitors. Fulvestrant (FASLODEX™), an estrogen receptor (ER) antagonist with no known agonist effects, competitively binds, blocks and degrades the ER. Vascular endothelial growth factor (VEGF) may mediate resistance to ER antagonists. Cediranib is a highly potent VEGF signaling inhibitor with activity against all three VEGF receptors. This randomized Phase II study evaluated cediranib plus fulvestrant. Postmenopausal women with hormone-sensitive metastatic breast cancer were eligible. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), duration of response, cl..View full abstract
Funding for this study was provided by AstraZeneca. We thank Dr Helen Jones, from Mudskipper Bioscience, who provided medical writing assistance funded by AstraZeneca.